显微视野计
医学
视网膜
眼科
糖尿病性视网膜病变
糖尿病性黄斑水肿
模式
光学相干层析成像
糖尿病
验光服务
内分泌学
社会科学
社会学
作者
Roomasa Channa,Risa M. Wolf,Rafael Simó,Mitchell Brigell,Patrice Elie Fort,Christine A. Curcio,Stephanie K. Lynch,Frank D. Verbraak,Michael D. Abràmoff,Michael D. Abràmoff,Roomasa Channa,Risa M. Wolf,Rafael Simó,Mitch Brigell,Patrice Elie Fort,Christine A. Curcio,Stephanie K. Lynch,Frank D. Verbraak,Thomas W. Gardner
标识
DOI:10.1016/j.xops.2023.100420
摘要
Topic: The goal of this review was to summarize the current level of evidence on biomarkers to quantify diabetic retinal neurodegeneration (DRN) and diabetic macular edema (DME). Clinical relevance: With advances in retinal diagnostics, we have more data on patients with diabetes than ever before. However, the staging system for diabetic retinal disease is still based only on color fundus photographs and we do not have clear guidelines on how to incorporate data from the relatively newer modalities into clinical practice. Methods: In this review, we use a Delphi process with experts to identify the most promising modalities to identify DRN and DME. These included microperimetry, full-field flash electroretinogram, spectral-domain OCT, adaptive optics, and OCT angiography. We then used a previously published method of determining the evidence level to complete detailed evidence grids for each modality. Results: Our results showed that among the modalities evaluated, the level of evidence to quantify DRN and DME was highest for OCT (level 1) and lowest for adaptive optics (level 4). Conclusion: For most of the modalities evaluated, prospective studies are needed to elucidate their role in the management and outcomes of diabetic retinal diseases. Financial Disclosures: Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
科研通智能强力驱动
Strongly Powered by AbleSci AI